Intelligence

#AI / data analytics / healthtech / informatics #Business #Clinical trials #Drug development #Enabling technologies #Regulatory #RNA

TMFs become key differentiator for CROs as stakeholders demand better collaboration and access

TMFs become key differentiator for CROs as stakeholders demand better collaboration and access By Rik Van Mol R&D outsourcing continues to rise sharply to meet the demands of life sciences organisations’ growing pipelines, but CROs have to keep evolving or more nimble competitors will take their place. Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #Genetics / genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Molecular medicine #PCR #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

Restucturing Proteomics: The rise of next-generation affinity reagents

Restucturing Proteomics: The rise of next-generation affinity reagents By Dr Paul Ko Ferrigno & Dr Jane McLeod The ability of antibodies to bind their target proteins with some degree of specificity has elevated them to being among the most useful tools in biology and medicine, with a market… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Flow Cytometry #High Content Screening #High throughput screening #Imaging #Immunology #Microbiology #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology

Cell Death: Discriminating between apoptosis, necrosis & autophagy

Cell Death: Discriminating between apoptosis, necrosis & autophagy By Dr John Abrams, Dr William G. Telford & Louise Rollins Cell death is crucial for the proper execution of normal and pathophysiological processes and is ubiquitous in biological systems. Programmed forms of cell… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Drug targets #Enabling technologies #High Content Screening #High throughput screening #Imaging #Immunology #Oncology #PCR #RNA #Screening #System biology #Systems biology #Translational #Translational chemistry

Immunoassay Automation: Hands-free platforms change the workflow

Immunoassay Automation: Hands-free platforms set to change the workflow in research labs By Dr John Comley The automation of immunoassays is not a new trend, but one that has already witnessed decades of innovation in diagnostic laboratories. However, in terms of hands-free automated processing of small batches of… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Chemical engineering #Chemistry #Clinical specialities #Drug discovery #Enabling technologies #High throughput screening #Mass spectrometry / NMR #Pathology #Regulatory #RNA #Screening #Toxicology

Redesigning Therapeutic Drug Monitoring for the 21st Century

Redesigning Therapeutic Drug Monitoring for the 21st Century By Lewis Couchman Therapeutic drug monitoring services are a vital part of the pathology laboratory’s remit, providing essential clinical information to guide the management and treatment of a wide range of patients, from those with psychiatric disorders to post-transplantation… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Business #Cell therapy #Clinical specialities #Computational chemistry #Drug development #Drug discovery #Drug repositioning #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #Lead discovery #Molecular medicine #Oncology #Orphan drugs #Protein chemistry / Proteomics #Regulatory #RNA #Sequencing #Stem cells #Toxicology

Data-mining Open Source Databases for Drug Repositioning Using Graph-Based Technique

Data-mining Open Source Databases for Drug Repositioning Using Graph-Based Technique By Dr Ken McGarry & Ukeme Daniel The analysis of ‘Big Data’ has great potential in drug discovery; however complications arise in integrating this data in a principled and coherent way. An… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biologics / Biotechnology #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug repositioning #Drug targets #Enabling technologies #Gene therapy #Genomics #High Content Screening #High throughput screening #Immunology / Virology & Vaccines #In Silico Biology #Lead discovery #Molecular medicine #Oncology #Orphan drugs #Patent Law #Pharmacology #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #System biology #Systems biology #Translational #Translational chemistry

Therapeutic Drug Repurposing, Repositioning and Rescue Part I: Overview

Therapeutic Drug Repurposing, Repositioning and Rescue Part I: Overview By Dr Stephen Naylor & Judge M. Schonfeld The pharmaceutical industry is still beleaguered by escalating costs, stagnant productivity and protracted timelines as it struggles to bring therapeutic drugs to market. This situation has been compounded by a ravenous… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Biologics / Biotechnology #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Flow Cytometry #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Lead optimisation #Medicinal chemistry #Molecular medicine #Oncology #Pharmacology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology #Translational #Translational chemistry

Opportunities For Phenotypic Screening In Drug Discovery

Opportunities For Phenotypic Screening In Drug Discovery By David C. Swinney Renewed awareness of the value of phenotypic screening to drug discovery creates many new opportunities to increase drug discovery success and productivity. These opportunities include identification of translational phenotypic biomarkers,… Read More

#Archive

#AI / data analytics / healthtech / informatics #Cell therapy #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Enabling technologies #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Immunology #Lead discovery #Molecular medicine #Oncology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #Therapeutics #Toxicology

Vector Mediated Therapeutics Based Upon DNA-Directed RNA Interference

Vector Mediated Therapeutics Based Upon DNA-Directed RNA Interference By Dr David Suhy A decade and a half after being first described to occur in mammalian cells, numerous trials are indicating that RNA interference can be harnessed to treat human disease. This article argues that positive results are… Read More

#Archive

#Analysis #Assay development optimisation & technology #Automation / robotics #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Microfluidics #Pharmacology #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Translational #Translational chemistry

Automated Patch Clamping Finally Achieves High Throughput

Automated Patch Clamping Finally Achieves High Throughput By Dr John Comley Two new third-generation automated patch clamp (APC) systems capable of high throughput processing (10,000 data points per eight-hour day) and full robotic integration have been recently launched. The resulting wider choice of primarily 384 APC systems has… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Drug discovery #Enabling technologies #Gene therapy #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #Oncology #Screening #Stem cells #Target validation

Industrial-Scale Screening Accelerates Discovery of Novel Drug Combination Therapies

Industrial-Scale Screening Accelerates Discovery of Novel Drug Combination Therapies By Dr Oliver Leven and Dr Eric Tang Drug combination therapies are widely recognised as essential therapeutic treatments for chronic conditions ranging from infectious diseases to cancer and HIV/AIDS. Such therapies can enhance a clinical efficacy profile, improve the… Read More

#Archive

#ADME / Tox #Business #Chemistry #Drug development #Drug discovery #Lead discovery #Pharmacology #Pharmokinetics #Preclinical #RNA #Screening #Toxicology

AstraZeneca’s Novel Approach To Monitor Primary DMPK Assay Performance

AstraZeneca’s Novel Approach To Monitor Primary DMPK Assay Performance By Dr Claire Landqvist, Brian Middleton, Dr Barry Jones and Dr Charles O’Donnell Drug This article discusses a novel approach by AstraZeneca to monitor primary DMPK assay performance & understand the inter and intra site assay variability. Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Business #Cell therapy #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #Lead discovery #Orphan drugs #Regulatory #RNA

Principles for Winning Digital Health Strategies

Principles for Winning Digital Health Strategies By Dr Thilo Kaltenbach In a recent study on digital health in the pharmaceutical industry, management consultancy Arthur D. Little provided an industry snapshot of pharmaceutical companies’ goals for 2020 and their progress so far. The study indicated that by 2020,… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #Lead optimisation #Molecular medicine #Precision medicine #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Translational #Translational chemistry

Advancing the Promise of Therapeutic Genomic Editing

Advancing the Promise of Therapeutic Genomic Editing By Dr Morgan L. Maeder and Dr David Bumcrot The development of genome editing technology is revolutionising the study of gene function and has the potential to usher in a new class of therapeutics for a broad range of diseases. Read More

#Archive

#Academic #Analysis #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #Lead discovery #Medicinal chemistry #Molecular medicine #Oncology #Orphan drugs #Pathology #Pharmacology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Reconfiguring Drug Discovery Through Innovative Partnerships

Reconfiguring Drug Discovery Through Innovative Partnerships By Dr Robert Grundy, Iain James, Chas Bountra and Timothy Harrison Attrition rates in drug discovery and development remain stubbornly high, despite large investments by the pharmaceutical industry. The cost of developing a new drug has been estimated at between $1.3 billion… Read More

#Archive

#Academic #Analysis #Biologics / Biotechnology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #High throughput screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Microbiology #Molecular medicine #Oncology #Regenerative Medicine #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

Cellular Raw Material Collection In Cell Therapy: Critical Determinant of Product Quality

By Dr Scott R. Burger, Louis Juliano, and Dr Wenshi Wang For more than two decades, the biotechnology and pharmaceutical industries have been working to unlock the great potential of cell therapy, which uses products composed of living, functional cells to mediate the therapeutic effect. Read More

#Archive